1. Volume 387, Issue 10023, Pages 1066-1074 (March 2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial 
Prof Jonathan A Ledermann, MD, Andrew C Embleton, MSc, Fharat Raja, BMBCh, Prof Timothy J Perren, MD, Prof Gordon C Jayson, PhD, Prof Gordon J S Rustin, MD, Prof Stan B Kaye, MD, Hal Hirte, MD, Prof Elizabeth Eisenhauer, MD, Michelle Vaughan, MB, Prof Michael Friedlander, MD, Antonio González-Martín, MD, Daniel Stark, MD, Elizabeth Clark, BSc, Laura Farrelly, MSc, Prof Ann Marie Swart, MB, Adrian Cook, MSc, Prof Richard S Kaplan, MD, Prof Mahesh K B Parmar, DPhil 
The Lancet 
Volume 387, Issue 10023, Pages (March 2016)
DOI: /S (15)
Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
SAE=serious adverse events. ITT=intention to treat. ECOG=Eastern Cooperative Oncology Group.
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Kaplan-Meier plot of progression-free survival over 2 years
Vertical reference line shows the median time to completion of the chemotherapy phase. Number at risk every 6 months shown with the number of failure events in parentheses, after the time in which the number at risk was calculated.
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3 Kaplan-Meier plot of overall survival over 3 years
Number at risk every 12 months shown with the number of failure events in parentheses, after the time in which the number at risk was calculated.
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions